ERBB3 and adenocarcinoma: Our results regarding the expression of EGFR, HER2 and HER3 are comparable to previously published results, with the possible exception of EGFR expression in I-type adenocarcinomas, where we found 3+ expression in 38% of the cases, compared with 4% expression [14] and 19% 3+ expression [15] in other studies.